Breaking News
May 26, 2018 - New research shows why babies need to move in the womb
May 26, 2018 - UK steps forward to tackle global antimicrobial resistance
May 26, 2018 - CRISPR-Cas9-based strategy allows researchers to precisely alter hundreds of different genes
May 26, 2018 - UT Southwestern-led researchers find new way to determine prognosis of invasive kidney cancer
May 26, 2018 - Researchers develop film to prevent bacteria from growing on dental retainers and aligners
May 26, 2018 - Mobile health intervention for people with serious mental illness as effective as clinic-based treatment
May 26, 2018 - Vaginal estradiol tablets outperform moisturizers when treating vulvovaginal problems
May 26, 2018 - Researchers call for new genetic tests for congenital diseases
May 26, 2018 - KHN’s ‘What the Health?’ Campaign promises kept, plus ‘nerd reports’
May 26, 2018 - Lung-on-a-chip technology could streamline drug-testing for pulmonary fibrosis
May 26, 2018 - Study finds early antibiotic initiation for majority of premature infants
May 26, 2018 - New environmental monitoring project finds increased numbers of deer ticks in Southern Indiana
May 26, 2018 - Pediatricians Should Advocate for Life Support Training
May 26, 2018 - Cannabidiol significantly reduces seizures in patients with severe form of epilepsy
May 26, 2018 - Allergies can have serious, far-reaching consequences on adolescents
May 26, 2018 - Scientists develop lab-based system to study mechanisms of common liver disease
May 25, 2018 - New guidelines may help pathologists to more accurately classify and diagnose invasive melanoma
May 25, 2018 - Immune cells promote lung cancer metastases by forming clots in tumors, study finds
May 25, 2018 - Can Excess Weight in Toddlers Cause Brain Drain?
May 25, 2018 - Studying insight
May 25, 2018 - Researchers reveal potent new mechanism of action for treatment of IBD
May 25, 2018 - Study shows lack of follow-up care for patients with concussion
May 25, 2018 - Study establishes the importance of haploid cells
May 25, 2018 - Coveted BMJ award bestowed on The Clatterbridge Cancer Center
May 25, 2018 - AACN outlines evidence-based protocols and clinical strategies to manage alarms
May 25, 2018 - Origami inspires researchers to develop new solution for tissue regeneration
May 25, 2018 - Melorheostosis – Genetics Home Reference
May 25, 2018 - Non-addictive pain medication changing therapy for substance use disorders
May 25, 2018 - Delayed lactate measurements in sepsis patients increase risk of in-hospital death
May 25, 2018 - Researchers identify novel epigenetic mutations as cause of neurodevelopmental, congenital disorders
May 25, 2018 - UD researchers examine connection between DNA replication in HPV and cancer
May 25, 2018 - Researchers identify neurons that play key role in aggressive behavior
May 25, 2018 - Snail’s eye inspires new type of RIOCATH urinary catheter
May 25, 2018 - Russian researchers develop high-tech device-transformer for ultrasound examination
May 25, 2018 - Researchers discover unexpected chemosensor pathway for predator odor-evoked innate fear behaviors
May 25, 2018 - Researchers build 3-D printer that offers sweet solution to making detailed structures
May 25, 2018 - Nearly one in three people know someone addicted to opioids
May 25, 2018 - Research suggests link between faulty gene, alcohol, and heart failure
May 25, 2018 - New findings could help fine-tune treatment for cancer patients
May 25, 2018 - New cancer treatment approach targets specific sugar receptors
May 25, 2018 - Skin responsible for uptake of cancer-causing compounds during barbecuing than lungs
May 25, 2018 - Early-onset cannabis use linked to further drug abuse problems
May 25, 2018 - Covered California takes aim at hospital C-section rates
May 25, 2018 - FDA Approves Palynziq (pegvaliase-pqpz) for the Treatment of Adults with Phenylketonuria
May 25, 2018 - Arthritis Glossary
May 25, 2018 - Study links breast cancer to the body’s internal clock
May 25, 2018 - Strenuous exercise in teenage years may protect against height loss later in life
May 25, 2018 - FDA approves novel enzyme therapy for adults with rare and serious genetic disease
May 25, 2018 - New research project aims at developing effective interventions for kids with DLD
May 25, 2018 - Middlemen who save $$ on medicines — but maybe not for you
May 25, 2018 - Study sheds new light on sharp rise in fatal drug overdoses in recent years
May 25, 2018 - Students propose revision of listeriosis guidelines for safer pregnancy
May 25, 2018 - TNFi Exposure In Utero Does Not Up Serious Infection Risk
May 25, 2018 - Organization of cells in the inner ear enables the sense and sensitivity of hearing
May 25, 2018 - Yoga May Be Right Move Against Urinary Incontinence
May 25, 2018 - Drinking recommended amount of milk could protect obese children against metabolic syndrome
May 25, 2018 - New cytokine network can repair tissue damage in the intestine, study finds
May 25, 2018 - Lyme disease researcher dispels misconceptions about ticks and provides prevention tips
May 25, 2018 - Penn researchers find link between social media usage and underage drinking
May 25, 2018 - Unique nanotechnology method to simplify skin disease diagnosis
May 25, 2018 - Study reveals new protective mechanism for tumor cells in breast cancer
May 25, 2018 - FRAME Alternatives Laboratory chosen for major European liver research collaboration
May 25, 2018 - Study shows yogurt may dampen chronic inflammation linked to multiple diseases
May 25, 2018 - Invasive cancers that are born to be bad show detectable differences from harmless tumors
May 25, 2018 - Study identifies new mechanism involved in development of Lou Gehrig’s disease
May 25, 2018 - UAB professor receives award for malaria prevention study in pregnant women in Cameroon
May 25, 2018 - Study provides blueprint of how fruit flies can be used to screen potentially pathogenic human genes
May 25, 2018 - New drug-delivering nanoparticle could offer better way to treat brain tumors
May 25, 2018 - Kessler Foundation scientists compare two tests for assessing learning in individuals with MS
May 25, 2018 - Stroke Symptoms and Diagnosis (Beyond the Basics)
May 25, 2018 - Protein goes against the family to prevent cancer
May 25, 2018 - Drugmakers blamed for blocking generics have milked prices and cost U.S. billions
May 25, 2018 - Speakers announced for National Medicines Symposium 2018
May 25, 2018 - GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
May 25, 2018 - Pfizer settles kickback case related to copay assistance for $24m
May 25, 2018 - Nuclear pore functions are essential for T cell survival
May 25, 2018 - Study defines molecular basis to explain connection between mother’s nutrition and infant growth
May 24, 2018 - IHI hosts representatives to develop a national action plan for patient safety
May 24, 2018 - Zika detection breakthrough by University of Queensland
May 24, 2018 - FDA Alert: 95% Ethyl Alcohol Product by Ethanol Extraction: Recall
New Models May Predict Progression in Early dcSSc

New Models May Predict Progression in Early dcSSc

image_pdfDownload PDFimage_print

Action Points

  • In early diffuse cutaneous systemic sclerosis (dcSSc), patients with shorter disease duration and less skin thickening were more likely to experience disease progression, and positivity for anti-RNA polymerase III (Pol3) indicated patients more likely to progress.
  • Note that researchers have not externally validated their predictive models based on skin thickening, disease duration and Pol3 positivity, and that will be an important step before they are used widely.

Two prediction models that may identify progression in early diffuse cutaneous systemic sclerosis (dcSSc) have been developed for clinical practice and randomized controlled trials, researchers reported.

The first predictive model, which included skin thickening measured by the modified Rodnan skin score (mRSS), disease duration, and the interaction between the two, had an accuracy of 60.9%, an area under the curve (AUC) of 0.666 and a positive predictive value (PPV) of 33.8%. By adding a variable for anti-RNA polymerase III (Pol3) positivity, the model reached an accuracy of 71%, AUC of 0.711, and PPV of 41%, according to Ariane L. Herrick, MD, of the University of Manchester in England, and colleagues.

“Among patients with early dcSSc, those with shorter disease duration and lower mRSS are most likely to be ‘progressors’ with a trade-off between the two factors and patients who are Pol3+ have the highest mRSS peaks and tend to reach peak mRSS earliest, providing a valuable message for clinicians that patients with short disease duration and Pol3+ must be especially closely monitored,” they wrote in the Annals of the Rheumatic Diseases.

While the model incorporating Pol3 more accurately identified high-risk patients, it may be too restrictive, they noted, adding that “both models were more flexible (for a given skin score) and more accurate than a ’22 mRSS’ cut-off model and may offer advantages for cohort enrichment in clinical trials to ensure that the most informative patients are included.”

Patients with dcSSc have high morbidity and mortality, which is associated with the degree of severity of skin fibrosis and thickening measured by the mRSS. The mRSS gauges skin thickness at 17 sites on a scale of 0 to 3, for a maximum score of 51. The skin score tends to progress rapidly in the first 3 to 5 years of dcSSc, then plateau and fall.

In the prospective European Scleroderma Observational Study (ESOS), researchers studied 326 adult patients with early dcSSc from 50 centers and 19 countries. Of the total sample, 65 patients started on methotrexate, 118 on mycophenolate mofetil, 87 on cyclophosphamide, and 56 had no immunosuppressant.

The primary outcome measure was the mRSS, which was recorded every 3 months. Because progression status did not significantly differ among treatment groups, the researchers analyzed mRSS trajectories regardless of treatment protocol. “Progressors” were defined as patients who experienced a 5-unit and 25% increase in mRSS over 12 months (±3 months).

In the study, 22.5% of early dcSSc patients progressed and 77.5% did not. Progression status could not be assessed in 33 patients.

At baseline, progressors had shorter disease duration (median 8.1 vs 12.6 months, P=0.001) and lower mRSS (median 19 vs 21 units, P=0.030) than nonprogressors.

Pol3+ patients had higher skin scores at baseline than patients in other autoantibody groups (P=0.003), despite similar disease durations (P=0.593). They seemed more likely to progress than other groups: 29.2% of Pol3+ patients were progressors, compared with 11.9% in the no-autoantibody group (P=0.105). Pol3+ patients had the highest peaks of all autoantibody groups, with a median peak of 35 units (P=0.001).

As a single predictor for progression, mRSS performed poorly with an AUC of 0.588. Duration of skin thickening performed better, with an AUC of 0.634. A model that combined mRSS, disease duration and the interaction between the two improved those univariate performances, with an AUC of 0.666. That model, known as model A, had 73.4% sensitivity, 57.2% specificity, and accurately predicted 60.9% of cases.

Adding an indicator variable for Pol3 positivity (model B) improved results. This yielded an AUC of 0.711, 60.4% sensitivity, 74.2% specificity, and accurately predicted 71% of cases.

“The key finding here was the development of a predictive model for mRSS (disease) progression which had an accuracy of 60.9%, achieved by recognizing that the initial skin score is a poor predictor of progression on its own and that prediction is improved by simultaneously accounting for disease duration,” the authors wrote. “By including autoantibodies in this analysis, the model improved and reached an accuracy of 71.0%.”

Model A can help inform randomized controlled trials, they noted, while model B can help identify patients at higher risk for progression in clinical settings. Using model B to inform patient selection into clinical trials may be too restrictive and could produce a sample that does not reflect the overall dcSSc population, they cautioned.

They added that by measuring skin scores every 3 months, they were able to capture peaks in mRSS that might not have been seen otherwise. “Had we only recorded baseline and 12-month data (two observations), 53% of our cases of progression would have been missed,” they wrote.

The study has several limitations, including the fact that, for some patients, peak mRSS may have occurred before they entered the study. Among patients whose progression status was unknown, 36.4% died, which might have induced bias.

Also, the researchers have not externally validated their models, adding that this will be an important step before they are used widely.

ESOS was funded by a grant from the European League Against Rheumatism Orphan Disease Programme, and Scleroderma, and Raynaud’s U.K.

Herrick and co-authors disclosed relationships with Actelion, Apricus, BMS, Celgene, Bayer, Boehringer Ingelheim, JB Therapeutics, Sanofi-Aventis, Novartis, Array BioPharma, Active Biotech, Galapagos, Medac, Pfizer, Anamar RuiYi, 4D Science, Biogenidec, BMS, EpiPharm, Ergonex, espeRare Foundation, Genentech/Roche, GSK, Inventiva, Lilly, Medac, Medimmune, Pharmacyclics, Serodapharm, Sinoxa ,UCB, Richter Gedeon, Inventiva, and Merck-Serono.


Tagged with:

About author

Related Articles